CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies

CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Decision Follows Robust Stakeholder Input and Creates Pathway for Enhanced Access and Coverage of Drugs that Receive Traditional FDA Approval Treatment for Alzheimer’s Disease Today, the Centers for Medicare & Medicaid Services (CMS) released a national policy for […]

Sotrovimab Monoclonal Antibody Treatment for COVID-19

As of April 5, 2022, the U.S. Food and Drug Administration (FDA) reissued the emergency use authorization (EUA) for GSK-Vir Biotechnology’s sotrovimab monoclonal antibody treatment. It is important to note Sotrovimab is no longer authorized for use within the U. S. The full FDA press release can be read at FDA updates Sotrovimab emergency use […]